LifeCell Corporation is now Allergan

ALLODERM SELECT™ Regenerative Tissue Matrix

ALLODERM SELECT™ Regenerative Tissue Matrix – The Surgeons' Choice, Now with Enhanced Precision1 

ALLODERM SELECT™ Regenerative Tissue Matrix is donated human dermis, processed to remove cells while preserving the essential biological components and structure of the dermal matrix to support regeneration.

Our gentle processing allows ALLODERM SELECT™ Tissue Matrix to support rapid revascularization, cell repopulation, and white cell migration, as shown in an animal study, offering surgeons a natural solution for soft tissue support where weakness exists.2*

*Correlation of these results to results in humans has not been established.

  1. Millennium Resources Group. 2015 US Breast Reconstruction Market Study; July 20, 2015. Study commissioned by LifeCell Corporation. Data on file
  2. Xu H, et al. Host response to human acellular dermal matrix transplantation in a primate model of abdominal wall repair. Tissue Eng Part A. 2008 Dec;14(12):2009-2019.
  3. Decision Resources Group Market Tracking Study: data. 2015. Study commissioned by LifeCell Corporation.
  4. Coverage policy analysis per JDC, LLC - data on file. Coverage of products represented by publicly available commercial policies as of March 2014. Number of covered lives by payor for top 10 payors represented: United 40M, Anthem BCBS 32M, Aetna 21M, CIGNA 13M, Humana 9M, HealthNet 5M, Highmark BCBS 5M, Independence BC 4M, CareFirst BCBS 3M, BCBS TN 3M = total of 135M covered lives. n = 40 publicly available policies with coverage of biologic brands for breast reconstruction procedures =179M covered lives total. Percentage obtained by dividing 135M covered lives for top 10 payors by total of 179M covered lives = 76%.
  5. AlloDerm is listed as medically necessary by the top 37 insurance carriers in the US with publicly available coverage policies for breast reconstruction procedures.  Other products are not listed as frequently, as of December 2015. Coverage policy analysis per Quorum Consulting Inc. Data on file.
  6. Federal Register, Vol. 80, No. 219, Part II, November 13, 2015. CMS-1633-FC. 42 CFR Parts 405, 410, 412, 413, 416, and 419. Medicare and Medicaid Programs: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs.